KR101493016B1 - A new use of traditional chinese medical composition - Google Patents

Abstract

The present invention discloses the application of a kind of Chinese medicine composition in the manufacture of a drug for treating myocardial dilatation. The Chinese medicine composition can effectively treat diastolic myocardial disease by effectively improving cardiac function and improving ventricular remodeling to a certain degree.

Chinese medicine composition, dilatation myocardial disease

Description

[0001] A NEW USE OF TRADITIONAL CHINESE MEDICAL COMPOSITION [0002]

The present invention relates to a new use of a medicinal composition (medicinal composition), and in particular, to the application of a medicinal composition of a kind in the manufacture of a medicament for treating myocardial infarction and for the treatment of myocardial infarction.

Dilated cardiomyopathy (DCM) refers to the enlargement of left ventricular or ventricular chambers and accompanied by myocardial hypertrophy. Since congestive heart muscle weakness mainly occurs, it was conventionally referred to as a congestive myocardial disease. Scalp myocarditis is the most common cardiomyopathy, accounting for about 70-80% of cardiomyopathy. Symptoms commonly seen are declining ventricular contractility, heartbeat abnormalities, and cardiac muscle weakness. Disease can be progressive, and death can occur at any stage of the disease. Clinically, it is possible to develop the disease evenly at each age, but middle age accounts for the majority. (Gene Australia << Practical Internal Medicine >> Tenth Edition. P1329-1333. People's Health Publishing Co.)

Scalp Myocardial infarction is increasing worldwide, and the cause of the disease has not been fully understood until now, and there are no specific treatment methods, and the disorder and death rate are high due to illness. Pharmacotherapy is still a universal and optimal choice for improving cardiac atrophy symptoms and controlling prognosis in patients with dilated cardiomyopathy. However, in some cases, the use of conventional anticonvulsive therapy and beta receptor blocker, angiotensin converting enzyme inhibitor (ACEI), has not yet obtained excellent effects.

Scalp myocardial infarction is the most common cause of cardiac muscle weakness, clinically characterized by cardiac enlargement, cardiac weakness, embolism, heartbeat abnormalities, and sudden death. Pathologic changes result in decreased myocardial cells, increased remnant myocardial cells, proliferating epilepsy collagen, thinning of the ventricular wall, and enlargement of the heart muscle. Because the cause of the disease is unclear, there is no specific treatment, there are problems such as poor prognosis, disability due to illness and mortality, high cost of heart transplantation, and the use of massive immunosuppressive drugs. We are constantly trying to improve the clinical symptoms and long-term prognosis of patients with dilated cardiomyopathy using other therapeutic agents.

The Chinese medicinal composition of the present invention improves blood flow kinetics, alleviates heart atrophy symptoms, and alleviates left ventricular remodeling through renin-angiotelisin system (RAS) I want to get the effect.

The present invention is an improvement on the basis of the Chinese patent ZL 02146573.8. The Chinese patent ZL 02146573.8 discloses a pharmaceutical composition for use in the treatment of cardiac weakness, and the present invention unexpectedly provides a novel therapeutic agent for the treatment of dilated cardiomyopathy, Medication &lt; / RTI &gt;

It is an object of the present invention to provide a kind of a Chinese medicine composition for application in the manufacture of a drug for treating myocardial infarction and its application in the treatment of myocardial infarction.

It is also an object of the present invention to provide a kind of herbal composition for application in the manufacture of a drug for treating myocardial infarction and for application in the treatment of dilated myocardial infarction.

It is also an object of the present invention to provide an application in the manufacture of a medicament for treating chronic cardiac muscle weakness due to dilatation myocardial infarction of a kind of Chinese medicine composition and its application in the treatment of chronic cardiac muscle weakness due to dilatation cardiomyopathy There is.

를 저하시키는 약물 제조에 있어서의 응용 및 확장성 심근병 중 혈청 뇌나트륨이뇨 펩타이드를 저하시키는데 있어서의 응용을 제공하고자 하는 데 있다. It is also an object of the present invention to provide a method of treating a cerebral sodium natriuretic peptide

In the manufacture of a medicament for lowering blood pressure and reducing the serum sodium natriuretic peptide in myocardial infarction.

It is also an object of the present invention to provide an application in the manufacture of a medicament for relieving myocardial necrosis during the treatment of myocardial infarction in a kind of Chinese medicine composition and its application in alleviating myocardial necrosis in dilated myocardial infarction.

It is also an object of the present invention to provide an application in the manufacture of a medicament for alleviating myocardial fibrosis in a dilated cardiomyocyte of a kind of Chinese medicine composition and its application in mitigating myocardial fibrosis in a dilated myocardial disease.

It is also an object of the present invention to provide a method for preparing a kind of myocardial disease drug composition.

Technical means of the present invention for realizing the above object are as follows.

150~450 중량부, 부자(附子) 40~120 중량부, 인삼(人蔘) 또는 당삼(黨蔘) 75~225 중량부, 단삼(丹蔘) 75~225 중량부, 정력자

(재쑥) 50~150 중량부, 향가피(香加皮) 또는 남오가피(南五加皮) 60~180 중량부, 택사(澤瀉) 75~225 중량부, 옥죽(玉竹) 25~75 중량부, 계지(桂枝) 30~90 중량부, 홍화(紅花) 30~90 중량부, 진피(陳皮) 25~75 중량부의 원료 약재로 제조된다. In the application of a kind of medicinal composition for the preparation of a medicament for treating myocardial infarction,

150 to 450 parts by weight, 40 to 120 parts by weight of supplemental ginseng, 75 to 225 parts by weight of ginseng or ginseng, 75 to 225 parts by weight of red ginseng,

50 to 150 parts by weight of a red pepper powder, 60 to 180 parts by weight of a scent of pepper or a southern gourd shell, 75 to 225 parts by weight of Tazawa, 30 to 90 parts by weight of safflower, 30 to 90 parts by weight of safflower and 25 to 75 parts by weight of dandelion.

In the preparation of a medicament for the treatment of a myocardial infarction of a kind of medicinal composition and for application in the treatment of dilated myocardial infarction, the medicinal composition comprises 150-450 parts by weight of sulfur, 40-120 parts by weight of ginseng, 75 to 225 parts by weight of ginseng, 75 to 225 parts by weight of ginseng, 50 to 150 parts by weight of chewing gum, 60 to 180 parts by weight of fragrance or soup oranges, 75 to 225 parts by weight of ginseng, 25 to 75 parts by weight of ginseng, 90 parts by weight, safflower 30 to 90 parts by weight, and dermis 25 to 75 parts by weight.

Application in the manufacture of a medicament for treating chronic cardiac muscle weakness due to dilatation myocardial infarction in a class of Chinese medicinal compositions and application in treating chronic cardiac muscle weakness due to dilatative myocardial infarction, 75 to 225 parts by weight of ginseng or sugar beet, 75 to 225 parts by weight of ginseng, 50 to 150 parts by weight of chewing gum, 60 to 180 parts by weight of fragrance or soup oranges, 75 to 225 parts by weight of ginseng 25 to 75 parts by weight of jade, 30 to 90 parts by weight of stitches, 30 to 90 parts by weight of safflower, and 25 to 75 parts by weight of dermis.

The above-mentioned Chinese medicine composition is preferably used in the preparation of a drug for lowering the serum brain sodium diuretic peptide during the treatment of dilatative myocardial disease and for application to lowering the serum brain sodium diuretic peptide during the treatment of dilated myocardial disease.

The above-mentioned Chinese medicine composition is preferably used in the manufacture of a medicament for alleviating myocardial necrosis during the treatment of dilatative myocardial infarction and for alleviating myocardial necrosis during the treatment of dilated myocardial disease.

The above-described Chinese medicine composition is preferably applied in the manufacture of a medicament for alleviating myocardial fibrosis during the treatment of dilated myocardial infarction, and for alleviating myocardial fibrosis during the treatment of dilated myocardial disease.

The herbal composition contains 450 parts by weight of sulfur, 112.5 parts by weight of ginseng, 225 parts by weight of ginseng or sugar, 225 parts by weight of ginseng, 150 parts by weight of persimmon, 75 parts by weight, the detergent 90 parts by weight, the safflower 90 parts by weight, and the dermis 75 parts by weight.

The Latin name of the medicinal raw material and its processing method in the medicinal composition of the present invention are as follows: &quot; Chinese medicinal preparations &quot; (July, 1977, 1st edition, Shanghai Science and Technology Publishing Co.) Publisher).

The active ingredient of the Chinese medicinal composition of the present invention can be prepared by the general extraction process [for example, Panzake Jing (Chinese medicinal chemistry) (Shanghai Science Publishing Co., December 1997 1st edition)], It is more preferable that the active ingredient of the composition is composed of the active ingredient obtained by the following procedure.

1) After extracting with Hwanggi, Tucker, Pharmacopoeia, Ginseng or Ganoderma lucidum, Phytophthora bacterium or Phytophthora bacterium with 70% ethanol and filtering, the extract becomes a dilute paste with relative density ranging from 1.25 to 1.30 at 50 ~ 70 ℃ Lt; / RTI &gt;

2) Volatile oil A, water solution B and drug residue C are obtained by extracting the volatile oil of the ducks and ducks with water.

3) Add water to make rich, red, gilt, safflower, and then filter the resulting aqueous solution to obtain filtrate D.

4) Filter the aqueous solution B after extracting the volatile oil from the dirt and dermis, collect the aqueous solution filtrate E, add water to the residue, add the medicinal residue C, and filter it to obtain the filtrate F.

5) The filtrate D, the filtrate E and the filtrate F are mixed and concentrated to a dilute paste having a relative density of 1.25 to 1.30. Ethanol is added in the course of stirring. When the alcohol concentration reaches 60 to 80% It is filtered and concentrated by filtration at 60 to 70 ° C to a dilute paste G having a relative density of 1.25 to 1.30.

6) The active ingredient which is the drug of the present invention is composed of the dilute paste, volatile oil A obtained in the process 1) and the dilute paste G obtained in the process 5).

The active ingredient of the Chinese medicine composition of the present invention may also be composed of the active ingredient obtained by the following process.

1) Extracts were extracted with an appropriate amount of 70% ethanol and filtered to obtain a dilute paste having a relative density of 1.25 to 1.30 (measured at a temperature of 60 ° C) Lt; / RTI &gt;

2) Extract the volatile oil of the stomach and dermis.

3) Add an appropriate amount of water to make rich, red, gilt, safflower, and then filter the obtained aqueous solution.

The aqueous solution after the oil is extracted from the glands and dermis is filtered, and the collected aqueous solution is filtered, and an appropriate amount of water is added to the filtrate to remove the residues, followed by filtration to mix the aqueous solution. The obtained various aqueous solutions were mixed and concentrated to a dilute paste having a relative density ranging from 1.25 to 1.30. Ethanol was added in the course of stirring. When the concentration of alcohol reached 70%, the mixture was allowed to stand and filtered. Concentrate the filtrate to a dilute paste of 1.25 to 1.30 (measured by heat).

The herbal composition of the present invention may also be subjected to a general preparation process. For example, according to the preparation process described in the &quot; Chinese Medicinal Chemistry &quot; (Shanghai Science Publishing Co., Ltd., December 1997, first edition), any conventional pharmaceutically acceptable formulations such as capsules, tablets, granules, It may be formulated with a preparation such as powder, solution, pill or the like.

In the application of the present invention, the herbal composition is a kind of a preparation such as a capsule, a tablet, a granule, a powder, a solution, a pill or the like and is a pharmaceutically acceptable adjuvant in preparing such a formulation, For example, fillers, disintegrants, lubricants, suspending agents, viscosity additives, sweeteners, mating agents, preservatives, ground substances and the like may be added. Examples of the filler include starch, pregelatinized starch, lactose, mannitol, chitosan, microcrystalline cellulose and sucrose. Examples of the disintegrant include starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, Low-substituted hydroxypropylcellulose, crosslinked sodium carboxymethylcellulose, and the like. Examples of the lubricant include magnesium stearate, sodium dodecylsulfate, talcum powder and silicon dioxide. Suspending agents include polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, and hydroxypropylmethyl cellulose. Examples of the viscous agent include starch paste, polyvinylpyrrolidone, and hydroxypropyl methylcellulose. Examples of the sweetening agent include sodium saccharin, aspartame, sucrose, molasses, glycyrrhetinic acid, and the like. Mating agents include sweeteners and various essences. Antiseptics include parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chlorhexidine acetate, and eucalyptus. The substrate includes PEG6000, PEG4000, insect wax, and the like. In order for the formulation to be able to realize the pharmacology of Chinese medicine, it is necessary to add other pharmacologically acceptable auxiliary materials when preparing such a formulation (the definition of "Chinese medicine", "Chinese Pharmacology", Shanghai Science Publishing Co., The auxiliary materials listed in each formulation in the first edition).

The dosage of the herbal composition of the present invention is preferably 4 to 20 g / day, preferably 1 to 2 times per day, and more preferably 6 to 12 g / day, in terms of the total weight of the active ingredient Is divided into two to four divided doses, preferably 7.59 g / day divided doses three times.

According to pharmacological experiments, the pharmaceutical composition of the present invention and the pharmaceutical preparation of the present invention can improve the contraction function of DCM heart-fallout rats and improve the nutritional status of heart-weakening rats, improve ventricular remodeling, It has been proven that it can cure heart muscle weakness. In order to demonstrate that the Chinese medicine composition of the present invention treats the activity of the dilated cardiomyopathy, the following animal experiment was conducted using the capsule content dry powder obtained in Example 1 (hereinafter referred to as the drug of the present invention).

Experimental Example 1)

1. Materials and Methods

1.1 Study subjects and group classification

Eighteen Wistar rats (Beijing Vital River Laboratory Animal Center, license number SCXK, 2002-0003) were randomly divided into 6 groups of normal (group A), dilated myocardial (abbreviated as DCM) heart Six debilitating groups (B group) and six drug groups (C group) of the present invention. The rats in group B and group C were treated with 2.5 mg / kg, 3 times / week, 1 time per day for adriamycin (manufactured by Shenzhen Longkou Pharmaceutical Co., Ltd., lot number 0407E1) Weekly for 2 weeks, and again for 1 week using a total of 6 injections of 15 mg / kg. After completion of the last injection, a DCM heart failure model was constructed by observing for 4 weeks. After the success of the model, the drug of the present invention (1 g of powder / kg, once / day) was stomach-intoxicated for 1 month in the C group, and physiological saline was observed in the A group and the B group for 1 month.

2. Observations and statistical methods

2.1 Observation index

2.1.1 Measurement of Serum Brain Sodium Diuretic Peptide (BNP)

All rats were treated with 1-1.5 ml of venous blood in an early morning fasting state for more than 30 minutes, and then serum was extracted by centrifugation at 3000 r / min for 15 minutes and stored at -20 ° C. The BNP assay was performed using a double-antibody sandwich ELISA method and KIT was purchased from Shanghai Deng Keng Technology Development Co., Ltd.

2.1.2 Measurement of cardiac function in rats:

All animals were anesthetized with 20% Urethane after the end of treatment, filled with heparinized saline in the catheter, inserted into the left ventricle from the right cervical ganglion, and perfused with a blood flow kinetics microcomputer analysis system泰 盟) to measure the function of the left ventricle. The left ventricular systolic pressure (LVEDP) and the left ventricular pressure maximal descending velocity (dp / dt max) are representative of the contraction function, and the indicators representing the relaxation function include the left ventricular end-diastolic pressure (LVEDP) -dp / dt max).

2.1.3 Detection of myocardial remodeling:

① Blood flow kinetics Measure the body weight (BW) of the rat after the measurement and then die to remove the heart. The total heart mass (HW / BW) and left ventricular mass index (LW / BW) are calculated by measuring the mass of the whole heart (HW) and the left ventricular mass (LW).

② A part of left ventricular myocardial tissue is taken and general hematoxylin-eosin staining (HE staining method) and collagen fiber staining method (V _G staining method) are performed to observe degree of myocardial necrosis and degree of fibrosis respectively. According to the standard (Blasing LE et al., Absolute and Relative Myocardial Bleeding due to Excessive Norepinephrine Biomedical Biochemistry (1985) 44: 1641), myocardial necrosis is classified as grade 4. Class Ⅰ: Stomach necrosis is limited to the lower endocardium. Class Ⅱ: Between necrosis of small necrosis and lesion are not connected, spread all over the floor. Class III: extensive platelet necrosis, connected between lesions, spread all over the floor. Class IV: Fusion necrosis spreading throughout the heart. V _G staining to observe the degree of interstitial fibrosis. Score recording standard: "-" Interstitial collagen fibers are not visible in multiple fields of view; "+" Intermittent epileptic interstitial fibers are occasionally seen; "++" when the epileptiform fiber has a long rope shape; "+++" when the epileptiform fibers are netted together.

2.2 Statistical Methods:

BNP and cardiac function were expressed as X ± S , and data were analyzed using statistical software SPSS 12.0, and P <0.05 was judged as significant difference. Comparisons between groups were performed using single factor ANOVA. The rank sum test was used to compare the degree of myocardial necrosis and interstitial fibrosis.

3. Results

3.1 Comparison of BNP results for each group (see Table 1)

Table 1 below compares the BNP results of each group ( X ± S ).

  Group A (n = 6)  B group (n = 6)  C group (n = 6) Before Treatment  1128.35 ± 256.32 1410.75 ± 97.09 ^★ 1462.44 + 242.87 ^* After treatment  1024.19 ± 204.29 1660.18 ± 210.87 ^{■ ▲} 1270.72 ± 203.72 ^{■ ▲} Note: In the comparison of the groups before and after treatment, P represents <0.05. Comparing groups B and C before treatment with group A, &amp; cir &amp; indicates P &lt; 0.05. In the comparison between the groups after treatment, P represents 0.05.

Results of BNP measurement showed that B group and C group had higher statistical significance than A group, and B group and C group had less statistical significance. Before and after the treatment of each group, the B group was higher than the control group before treatment and the C group was lower than the control group before treatment. There was no statistical significance between group A and group B. After treatment group B and group C were higher than group A, group C was lower than group B, and group C was higher than group A , All of which have statistical significance.

3.2 Comparison of cardiac function results for each group (see Table 2):

Table 2 below compares the cardiac function results of each group ( X ± S )

 LVSP (Kpa) dp / dt _max (Kpa / s) LVDEP (Kpa) -dp / dt _max (Kpa / s) Group A (n = 6)  19.58 ± 1.87  842.60 ± 86.18  -0.82 +/- 1.24  550.00 ± 89.53 B group (n = 6) 13.62 ± 1.44 ^▲ 564.00 ± 72.77 ^▲ 0.34 ± 1.15  449.80 ± 59.90 C group (n = 6) 16.76 ± 3.17 ^{● ■} 721.40 ± 115.10 ^{● ■}  -0.04 ± 0.82  542.40 ± 76.92  Note that in the comparison between the B group and the A group,? Represents P < 0.05, and? Represents P? 0.05 in the comparison of the C group and the B group, .

In the posttreatment results, the contraction function index LVSP, dp / dt _max was lower than that of the A group, and the C group was higher than the B group, all having statistical significance. In comparison of the C group and the A group, It was not found to be meaningful. LVDEP and -dp / dt _max , the indicators of relaxation function, did not show any significant difference in comparison between the three groups.

3.3 Comparison of body weight, total cardiac mass index and left ventricular mass index of each group (see Table 3):

Table 3 below compares the body weight, total cardiac mass index and left ventricular mass index of each group ( X ± S ).

 BW (g)  HW / BW (g / kg)  LW / BW (g / kg) Group A (n = 6)  359.43 + - 22.56  2.71 ± 0.17  2.14 ± 0.19 B group (n = 6) 272.57 ± 16.54 ^▲ 2.17 ± 0.17 ^▲ 1.77 ± 0.15 ^▲ C group (n = 6)  308.80 ± 6.30 2.66 ± 0.40 ^■ 2.07 ± 0.20 ^■ Note: In the comparison between the B group and the A group,? Represents P < 0.05, and? Represents P < 0.05 in the comparison of the C group and the B group.

In the results after treatment, the BW of the B group was significantly lower than that of the A group and statistically significant. The C group was higher than the B group but not statistically significant, and the C group and the A group had no statistical significance Respectively. HW / BW and LW / BW were lower in group B than in group A, and group C was higher than group B, which had statistical significance. The comparison between group C and group A is not statistically significant.

3.4 Results of myocardial necrosis and degree of fibrosis in each group (see Table 4):

Table 4 below compares the degrees of myocardial necrosis and fibrosis in each group.

 Mean rank of degree of myocardial necrosis  Mean ranking of myocardial fibrosis Group A (n = 6)  21   21 B group (n = 6) 72.5 ^▲ 78.5 ^▲ C group (n = 6) 50.5 ^{▲ △} 51.5 ^{▲ △}  Note: In each of the B group, the C group and the A group,? Represents P <0.01, and? Represents P <0.05 in the comparison of the C group and the B group.

In the results of the treatment, the degree of myocardial necrosis: the B group and the C group were statistically more important than the A group, the C group had milder statistical significance than the B group, and the myocardial fibrosis degree: Group A had higher statistical significance than group A, and group C had lower statistical significance than group B.

In the accompanying drawings, FIG. 1 is a microscopic view (HE x 100) in which the rat myocardium of Group A is stained by a general HE staining method, and shows that myocardial cells and myofibril arrangement are uniform, . FIG. 2 is a microscopic view (HE x 100) in which the rat heart myocardium of Group B was stained with HE staining method, showing that myocardial cell arrangement was disrupted, nuclei of some cells disappeared, and cytosol was lightly stained necrotic myocardial cells can see. FIG. 3 is a microscopic view (HE x 100) in which the myocardium of the C group rats was stained (HE x 100) by the general HE staining method. The myocardial cell and myofibril arrangement was arranged more than the cardiac decongestant group, 4 is a microscopic view (HE x 100) in which the myocardium of group B rats was stained with normal HE staining method, showing that a large portion of myocardial cells were necrotic. FIG. 5 is a microscopic view (HE x 100) of a group B of a large mouse myocardium stained by HE staining method, showing that a large portion of myocardial cells are necrotic and myofibrils are broken. 1 to 5, the degree of myocardial necrosis and myocardial fibrosis after administration of the medicament of the present invention were significantly lower than those of the heart failure group. FIG. 6 is a micrograph showing the myocardium of group B rats stained (V _G × 100) by a general V _G staining method, in which a large amount of rope-shaped interstitial collagen fibers can be seen and indicated by ++. FIG. 7 is a microscopic view (V _G × 100) of the myocardium of the C group rats by the general V _G staining method. The short interstitial collagen fibers scattered can be seen and marked with +. 6 to 7, after the drug treatment of the present invention, it can be seen that the myocardial cell epilepsy fiber was significantly reduced.

In the present invention, a method of injecting adriamycin into the peritoneal cavity was employed to produce a cardiac decay model of DCM rats. After one month of treatment with the drug of the present invention, the LVSP and dp / dt _max is higher than that of the heart failure group and has statistical significance. The LVDEP and -dp / dt _max representative of the relaxation function were not statistically significant as compared to the cardiac atrophy group, demonstrating that the drug of the present invention significantly improved the contractile function of DCM rats but did not improve the relaxation function do. BNP is a polypeptide with 32 amino acids that is secreted mainly from the ventricles and represents responses to ventricular volume expansion and pressure loading. In a large number of studies both at home and abroad, it has already been demonstrated that BNP acts as a serum / plasma marker of cardiac muscle weakness and is used in the diagnosis, treatment, and prognostic evaluation of cardiac muscle weakness. The results of the present study showed that serum BNP levels in the rats of the heart-weakening group were significantly higher than those of the normal group, and after the gastrointestinal treatment of the drug of the present invention, the BNP levels were significantly lowered, And that the drug of the present invention can significantly improve the cardiac function of DCM rats. The HW / BW and LW / BW of the cardiac atrophy group are significantly lower than the normal group, consistent with changes in DCM. After treatment, HW / BW and LW / BW were increased and also had statistical significance, demonstrating that the medicament of the present invention can improve ventricular remodeling. The degree of myocardial necrosis and the degree of epilepsy fibrosis in the drug group of the present invention were significantly reduced as compared with those in the heart failure group. This explains that the drug of the present invention can inhibit myocardial necrosis and prevent ventricular remodeling due to myocardial fibrosis.

Experimental Example 2) Clinical Experiment:

1. Clinical data

1.1 General data: All 60 selected pathologies were outpatient clinics between 2005 and 2006 in Hebei Hospital, of which 38 cases were males and 22 cases were females. Twelve cases were 45 to 55 years old by age, 28 cases from 56 to 65 years old, and 20 cases from 66 to 74 years old.

1.2 Screening standards: All meet the WHO diagnostic standard. Ultrasonography showed that the heart was enlarged, the wall of the ventricles became thinner, and myocardial diffuse pulsation was reduced. ② We excluded maternal heart disease with coronary heart disease, rheumatic heart disease, congenital heart disease, viral myocarditis and other various causes.

1.3 Therapeutic Efficacy Standard: Clinical healing is seen when clinical symptoms such as palpitation, edema, etc. are lost, heart sounds are markedly reduced, and heart failure is corrected. After treatment, edema is diminished, cardiac hypertension is relieved, heart rate is slightly reduced, and if clinical symptoms are not clear after treatment, it is considered invalid.

2. Methods of treatment: All the cases were treated with the capsule prepared by the method according to Example 1 of the present invention three times a day, three times each time, the medication cycle was one to three times, and each treatment period was one month , With an interval of one week between treatments.

3. Results: Clinically, 42 cases were healed, 17 cases were improved, 1 case was invalid, and the total effective rate was 98%. Patients who do not have normal cardiac enlargement can lose their post-medication edema, relieve hypertrophy and shortness of breath during a single course of treatment, and clinically heal if they are taking medication for four times. Severe patients with a wide range of cardiothoracic spells had lost postprandial edema during the two treatment sessions, relieved symptoms of palpitations and shortness of breath, and reduced the liver and spleen. During the four treatment sessions, the patient was able to control heart failure after medication and all clinical symptoms were significantly reduced.

4. Conclusion: The drug of the present invention is effective in treating myocardial infarction.

[Example 1]

Capsule

Prescription:

450g of Hwanggi, 112.5g of rich, 225g of ginseng, 225g of ginseng, 150g of tincture, 150g of fragrant pear, 180g of phytophthora, 225g of safflower, 90g of safflower,

Preparation method:

(1) Hwanggi, Tucker, Pharmacia, Ginseng and Fructus were recovered with 70% ethanol by adding 8 times (weight ratio) according to the prescription, and extracted twice for 1 hour for 3 hours and 2 hours for 2 hours. The solution was mixed and filtered, and the filtrate was reduced in pressure to recover ethanol. The concentrate was then concentrated to a dilute paste having a relative density of 1.25 to 1.30 (measured at 60 ° C).

(2) The wax and the dermis are distilled in proportions to extract volatile oil, and the aqueous solution after the extraction is prepared by filtration. The residue is further added with 8 times of water, stirred for 1 hour, and then filtered to prepare an aqueous solution .

(3) Add 9 times (weight ratio) of water to rich, red ginseng, japanese, safflower and drink twice. The extracts are mixed and filtered each time for 2 hours, and the wicks, dermis solutions in step 2) are mixed and then concentrated to a dilute paste having a relative density of 1.25 to 1.30 (measured in 60 ° C heat) Ethanol was added and ethanol was recovered when the alcohol concentration reached 70% and the mixture was allowed to stand still at 4 ° C or lower for 24 hours. The filtrate was reduced in pressure to recover ethanol, and the relative density reached 1.25 to 1.30 The mixture is concentrated to a dilute paste, mixed with the alcohol-extracted dilute paste of step (1), and dried at 65 to 70 ° C.

(4) The dried paste was mixed and pulverized into 100 mesh powder, and 70% ethanol was added thereto to prepare granules. The granules and the dermis volatile oil were sprayed, uniformly mixed, and then packed in capsules to prepare 1000 eggs .

DOSAGE AND ADMINISTRATION: Take 4 tablets daily, 3 times daily, for the treatment of dilatation myocardial infarction.

[Example 2]

Preparation of active ingredients

Prescription:

450g of Hwanggi, 112.5g of rich, 225g of ginseng, 225g of ginseng, 150g of tincture, 150g of fragrant pear, 180g of phytophthora, 225g of safflower, 90g of safflower,

Preparation method:

1) After extracting with Hwanggi, Tucker, Pharmacopoeia, Ginseng or Ganoderma lucidum, Flavobacterium or Southern blotch with 70% ethanol, extract the solution until it becomes a thin paste with relative density of 1.25 ~ 1.30 at 50 ~ 70 ℃ Concentrate.

2) Volatile oil A, water solution B and drug residue C are obtained by extracting the volatile oil of the ducks and ducks with water.

3) Add water to make rich, red ginseng, jade, and safflower, and filter the obtained aqueous solution to obtain filtrate D.

4) After extracting the volatile oil from the ducks and dermis, filter the aqueous solution B to collect the aqueous solution filtrate E, add water, add the chemical residue C, and filter it to obtain the filtrate F.

5) Filtrate D and filtrate E The filtrate F is mixed and concentrated to a dilute paste having a relative density of 1.25 to 1.30. Ethanol is added during the stirring to adjust the alcohol concentration to 60 to 80% As soon as possible, the mixture is filtered, and the filtrate is concentrated at 60 to 70 ° C until it becomes a dilute paste G having a relative density of 1.25 to 1.30.

6) The active ingredient of the medicinal composition is composed of the dilute paste obtained in step 1), the volatile oil A, and the dilute paste G obtained in step 5).

[Example 3]

Capsule

Prescription:

450g of Hwanggi, 112.5g of rich, 225g of ginseng, 225g of ginseng, 150g of tincture, 150g of soup, 200g of soup, 225g of ginseng, 90g of safflower, 75g of ginseng, 75g of ginseng and 90g of ginseng

Prepare 1000 capsules as a general process.

DOSAGE AND ADMINISTRATION: Take 4 tablets daily, 3 times daily, for the treatment of dilatation myocardial infarction.

[Example 4]

Granule

Prescription:

450g of Hwanggi, 112.5g of rich, 300g of ginseng, 225g of ginseng, 150g of tincture, 200g of soup, 225g of ginseng, 90g of safflower, 75g of ginseng, 75g of ginseng and 90g of ginseng

It is used in the treatment of dilatation myocardial infarction.

FIG. 1 is a microscopic view of the heart of a group A rat stained with a general HE stain method.

Fig. 2 is a microscopic view of staining myocardial muscle of group B rats with general HE staining method.

Fig. 3 is a microscopic view of the myocardium of group C rats stained with general HE staining method.

Fig. 4 is a microscopic chart showing the myocardial muscles of group B rats stained with general HE staining method.

FIG. 5 is a microscopic view of staining myocardial muscles of group B rats using general HE staining method.

FIG. 6 is a microscopic view of the myocardium of Group B rats stained with normal V _G staining.

FIG. 7 is a microscopic view of the myocardium of Group C rats stained with normal V _G staining.

Claims (22)

(B) 50-150 parts by weight of ginseng, 50-150 parts by weight of ginseng or ginseng, 60-180 parts by weight of ginseng or ginseng, 150 ~ 450 parts by weight of ginseng, 75 ~ 225 parts by weight of ginseng or ginseng, 75 ~ 225 parts by weight ginseng, , 75 to 225 parts by weight of phytopathogenic fungi, 25 to 75 parts by weight of jade, 30 to 90 parts by weight of stipes, 30 to 90 parts by weight of safflower and 25 to 75 parts by weight of dermis. Chinese medicine composition for preparation (medicinal composition). The method according to claim 1, The herbal composition contains 450 parts by weight of sulfur, 112.5 parts by weight of ginseng, 225 parts by weight of ginseng or sugar, 225 parts by weight of ginseng, 150 parts by weight of persimmon, 75 parts by weight, a detergent of 90 parts by weight, safflower of 90 parts by weight, and a dermis of 75 parts by weight. The method according to claim 1, The active ingredient of the above- 1) After extracting with a proper amount of 70% ethanol and filtering the extract, the extract is diluted paste having a relative density of 1.25 ~ 1.30 when measured at 60 ℃. &Lt; / RTI &gt; 2) extracting the volatile oil of the ducks and dermis, 3) Add an appropriate amount of water to make rich, sweet ginseng, jade, safflower, and filter the obtained aqueous solution; After the oil is extracted from the wool, duck, and duck, the aqueous solution is filtered to collect an aqueous filtrate, and then an appropriate amount of water is added to remove the residue, filtrate to mix the aqueous solution; The various aqueous solutions obtained as described above were mixed and concentrated to a dilute paste having a relative density of 1.25 to 1.30 when measured at a temperature of 60 캜. Ethanol was added in the course of stirring. When the alcohol concentration reached 70%, the mixture was filtered , Concentrating the filtrate to a dilute paste having a relative density of 1.25 to 1.30 when measured at 60 ° C &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof. The method according to claim 1, The active ingredient of the above- 1) After extracting with a proper amount of 70% ethanol and filtering the extract, the extract was diluted with a relative density of 1.25 ~ 1.30 when measured at 50 ~ 70 ℃. Lt; RTI ID = 0.0 &gt; 2) obtaining volatile oil A, aqueous solution B and drug residue C by extracting the volatile oil of the ducks and ducks with water, 3) adding water to make rich, red ginseng, jade, safflower, and filtering the obtained aqueous solution to obtain a filtrate D; 4) collecting the aqueous solution filtrate E by filtration of the aqueous solution B after extracting the volatile oil from the dirt and dermis, adding water to the medicinal material residue C, filtering the filtrate F to obtain the filtrate F, 5) Filtrate D, Filtrate E Filtrate F is mixed and concentrated to a dilute paste having a relative density of 1.25 to 1.30. Ethanol is added in the course of stirring, and when the alcohol concentration reaches 60 to 80% And then filtrating and concentrating the filtrate at 60 to 70 DEG C to a dilute paste G having a relative density of 1.25 to 1.30, 6) Constituting the active ingredient of the medicinal composition with the dilute paste G obtained in step 1), volatile oil A and the dilute paste G obtained in step 5) &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof. 5. The method according to any one of claims 1 to 4, Wherein the myocardial disease is a dilated myocardial disease. 6. The method of claim 5, Wherein said Chinese medicine composition is applied to a drug for treating chronic cardiac muscle weakness due to dilated myocardial infarction. 6. The method of claim 5, Wherein said medicinal composition is applied to a drug for lowering serum brain sodium diuretic peptide. 6. The method of claim 5, Wherein said Chinese medicine composition is applied to a drug for alleviating myocardial necrosis. 6. The method of claim 5, Wherein said Chinese medicine composition is applied to a drug that alleviates myocardial fibrosis. 5. The method according to any one of claims 1 to 4, The medicinal preparation formulated with said medicinal composition is a capsule, tablet, granule, powder, solution or pill. 6. The method of claim 5, The medicinal preparation formulated with said medicinal composition is a capsule, tablet, granule, powder, solution or pill. (B) 50-150 parts by weight of ginseng, 50-150 parts by weight of ginseng or ginseng, 60-180 parts by weight of ginseng or ginseng, 150 ~ 450 parts by weight of ginseng, 75 ~ 225 parts by weight of ginseng or ginseng, 75 ~ 225 parts by weight ginseng, Wherein the raw material is prepared from a raw material of 75 to 225 parts by weight of talc, 25 to 75 parts by weight of jade, 30 to 90 parts by weight of interlocking stones, 30 to 90 parts by weight of safflower and 25 to 75 parts by weight of dermis. Lt; / RTI &gt; 13. The method of claim 12, The herbal composition contains 450 parts by weight of sulfur, 112.5 parts by weight of ginseng, 225 parts by weight of ginseng or sugar, 225 parts by weight of ginseng, 150 parts by weight of persimmon, 75 parts by weight, the detergent is 90 parts by weight, the safflower is 90 parts by weight, and the dermis is 75 parts by weight. 13. The method of claim 12, The active ingredient of the above- 1) After extracting with a proper amount of 70% ethanol and filtering the extract, the extract is diluted paste having a relative density of 1.25 ~ 1.30 when measured at 60 ℃. &Lt; / RTI &gt; 2) extracting the volatile oil of the ducks and dermis, 3) Add an appropriate amount of water to make rich, sweet ginseng, jade, safflower, and filter the obtained aqueous solution; After the oil is extracted from the wool, duck, and duck, the aqueous solution is filtered to collect an aqueous filtrate, and then an appropriate amount of water is added to remove the residue, filtrate to mix the aqueous solution; The various aqueous solutions obtained as described above were mixed and concentrated to a dilute paste having a relative density of 1.25 to 1.30 when measured at a temperature of 60 캜. Ethanol was added in the course of stirring, and when the alcohol concentration reached 70%, the mixture was filtered , Concentrating the filtrate to a dilute paste having a relative density of 1.25 to 1.30 when measured at 60 ° C &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof. 13. The method of claim 12, The active ingredient of the above- 1) After extracting with an appropriate amount of 70% ethanol and filtering, the extract is diluted with a relative density of 1.25 ~ 1.30 at 50 ~ 70 ℃. &Lt; / RTI &gt; 2) obtaining volatile oil A, aqueous solution B and drug residue C by extracting the volatile oil of the ducks and ducks with water, 3) adding water to make rich, red ginseng, jade, safflower, and filtering the obtained aqueous solution to obtain a filtrate D; 4) filtering the aqueous solution B after extracting the volatile oil from the dirt and dermis, collecting the aqueous solution filtrate E, adding water again to obtain the medicinal residue C, and then filtering to obtain the filtrate F, 5) Filtrate D, Filtrate E Filtrate F is mixed and concentrated to a dilute paste having a relative density of 1.25 to 1.30. Ethanol is added in the course of stirring, and when the alcohol concentration reaches 60 to 80% And then filtrating and concentrating the filtrate at 60 to 70 DEG C to a dilute paste G having a relative density of 1.25 to 1.30, 6) Constituting the active ingredient of the medicinal composition with the dilute paste G obtained in step 1), volatile oil A and the dilute paste G obtained in step 5) &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof. 16. The method according to any one of claims 12 to 15, Wherein the myocardial disease is a dilated myocardial disease. 17. The method of claim 16, Wherein said Chinese medicine composition is applied to a drug for treating chronic cardiac muscle weakness due to dilated myocardial infarction. 17. The method of claim 16, Wherein said medicinal composition is applied to a drug for lowering serum brain sodium diuretic peptide. 17. The method of claim 16, Wherein said Chinese medicine composition is applied to a drug for alleviating myocardial necrosis. 17. The method of claim 16, Wherein said Chinese medicine composition is applied to a drug that alleviates myocardial fibrosis. 16. The method according to any one of claims 12 to 15, The medicinal preparation formulated with said medicinal composition is a capsule, tablet, granule, powder, solution or pill. 17. The method of claim 16, The medicinal preparation formulated with said medicinal composition is a capsule, tablet, granule, powder, solution or pill.

Images